CAMI Health - Coalition Advancing Multipurpose Innovations Together for Women’s Health Empowerment
Excuse the dust! We are in the process of transitioning the CAMI Health resource center to our new site.
Until the move is complete, we invite you to continue using this version of the resource center. Thank you for your patience!

Highlighted Articles

Articles on MPTs

Multipurpose Prevention Technologies: Maximising Positive Synergies
Special Issue. BJOG: An International Journal of Obstetrics & Gynaecology. October 2014, 121(s5): 1-103.

Multipurpose prevention technologies: maximizing positive synergies
Lusti-Narasimhan M, Merialdi M, Young Holt B. BJOG, 6 JAN 2014. | DOI: 10.1111/1471-0528.12606

Multipurpose prevention technologies
Lusti-Narasimhan M, Merialdi M, Young Holt B. Entre Nous No. 79, 2013; 18-20.

Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies
Special Supplement, Antiviral Research, 100 (2013) S1-S60.

Developing Multipurpose Reproductive Health Technologies: An Integrated Strategy
Harrison PF, et al. AIDS Research and Treatment, Volume 2013.

Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies
Thurman AR, Clark MR, Doncel GF. Infect Dis Obstet Gynecol. August 2011.

Multipurpose methods: New prevention option?
Bowers R. Contraceptive Technology Update. September 2010, 31(9): 104-106.

Multipurpose Prevention Technologies for Sexual and Reproductive Health: Gaining Momentum and Promise
Holt BY, Kilbourne-Brook M, Stone A, Harrison P, and Shields W. Contraception. 2010, Vol 81: 177-180.

All Articles

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
Abdool Karim Q, et al. Science. 2010 Sep 3;329(5996):1168-74. 

Teaching Good Sex
Abraham L, New York Times Magazine. 20 Nov. 2011.

Lactococcus Lactis-Based Vaccines: Current Status and Future Perspectives
Bahey-El-Din M, Gahan Cormac, Human Vaccines. January 2011 7(1) 1-4.

The Need for a Revitalized National Research Agenda On Sexual and Reproductive Health
Barot S, Guttmacher Policy Review. Winter 2011 14(1) 16-22.

Efficacy Results of a Trial of a Herpes Simplex Vaccine
Belshe RB, et al. New England Journal of Medicine. 2012; 366:34-43.

Drug Compound Wipes Out Multiple Viral Infections
Berman J, Voice of America. 20 August 2011.

Sociocultural Issues in the Introduction of Human Papillomavirus Vaccine in Low-Resource Settings
Bingham A, DrakeJK, LaMontagne DS. Archives of Pediatric & Adolescent Medicine. May 2009, Vol 163,5:455-461.

An Approach to Formative Research in HPV Vaccine Introduction Planning in Low-Resource Settings
Bingham A, Janmohamed A, Bartolini R, Creed-Kanashiro HM, Katahoire AR, Khan I,et al. The Open Vaccine Journal. 2009, Vol 2.

Innovative public-private partnerships to maximize the delivery of anti-malarial medicines:  lessons learned from the ASAQ Winthrop experience
Bompart F, Kiechel JR, Sebbag R, Pecoul B. Malaria Journal, 2011. Vol 10:143.

Linkages between HIV and Family Planning Services under PEPFAR: Room for Improvement
Boonstra H, Guttmacher Policy Review. Fall 2011 14(4).

Multipurpose methods: New prevention option?
Bowers R. Contraceptive Technology Update. September 2010, 31(9): 104-106.

Facilitating Regulatory Approval of Multipurpose Prevention Technologies for Sexual and Reproductive Health
Brady M.  New York: Population Council, 2011.

Insights and Evidence from product Introduction: Lessons for Microbicides
Brady M, McGrory E. USAID, Population Council, New York, 2007.

What Regulatory Guidance Exists for Multipurpose Prevention Technologies (MPTs)? A Review of Key Guidance Documents and Their Applicability to MPTs
Brady M, Park H, USAID, Population Council, New York, July 2011.

Facilitating Regulatory Approval of Multipurpose Prevention Technologies for Sexual and Reproductive Health
Brady M, USAID, Population Council January 2011.

Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk
Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallet TB
AIDS 2013, 27: 105-113

Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies
Castellsague X, Diaz M, Vaccarella S, de Sanjose S, Munoz N, Herrero R, et al. The Lancet.

Hormonal contraception and HIV risk: evaluating marginal-structural-model assumptions
Chen L, Cole SR, Morrison CS, Epidemiology. November 2011 22(6) 877-8.

Family Planning as a Cost-Saving Preventive Health Service
Cleland K, Peipert J, Westhoff C, Spear S, Trussell J, New England Journal of Medicine.

Public-private partnerships: from there to here
Croft SL. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2005, 99S:S9-S14.

Safety and Immunogenicity of Three Different Formulations of a Liquid Hexavalent Diphtheria–Tetanus–Acellular Pertussis–Inactivated Poliovirus–Haemophilus Influenzae B Conjugate–Hepatitis B Vaccine at 2, 4, 6 and 12–14 Months of Age
Diaz-Mitoma F, Halperin S, Tapiero B, Hoffenbach A, Zappacosta P, Radley D, et al., Vaccine. 29(2011) 1324-1331.

Induction of Immune Memory by a Multisubunit Chlamydial Vaccine
Eko FO, Ekong E, He Q, Black CM, Igietseme JU, Vaccine. 29 (2011) 1472-80.

Split in AIDS and family planning fails girls
Fox H, Deutsche Welle. 20 May 2011.

Focus on HIV-Aids cost family planning a decade, says UN population chief 
Goldenberg S, The Guardian, 24 October 2011.

Reflections on Innovative Medicines Initiative
Goldman M. Nature Reviews Drug Discovery. May 2011, Vol 10:321-322.

Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study
Heffron R, et al. The Lancet Infectious Diseases. Published online 4 October 2011. DOI:10.1016/S1473-3099(11)70247-X.

Multipurpose Prevention Technologies for Sexual and Reproductive Health: Gaining Momentum and Promise
Holt BY, Kilbourne-Brook M, Stone A, Harrison P, and Shields W. Contraception. 2010, Vol 81: 177-180.

Hormonal contraception and HIV acquisition risk: implications for individual users and public policies
Jain AK. Contraception. 2012.  In Press 

Impact of Integrated Family Planning and HIV Care Services on Contraceptive Use and Pregnancy Outcomes: A Retrospective Cohort Study
Kosgei J, Lubano KM, Shen C, Wools-Kaloustian KK, Musick BS, Silka AM, et al., Journal of Acquired Immune Deficiency Syndromes. 15 December 2011  58 (5) 121-26.

The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership
Lacaze C, et al.Malaria Journal. 2011, Vol 10:142.

Failed herpes vaccine puzzles virologists
Ledford H. Nature. Epub 4 January 2012.

Transfer of IgG in the Female Genital Tract by MHC Class I-related Neonatal Fc Receptor (FcRn) Confers Protective Immunity to Vaginal Infection
Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian D, Zhu X, PNAS 15 March 2011 108(11) 4288-4394.

FcRn Supporting Information
Li et al 10.1073/pnas.10128608

Vaginal rings for delivery of HIV microbicides
Malcolm RK, et al. Int J Womens Health. 2012; 4: 595–605.

Immunogens and Antigen Processing: Report from a Global HIV Vaccine Enterprise Working Group
Mascola J, King CR, Steinman R, Nature Precedings.

Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe
Morrison CS, Chen PL, Nankya I, Rinaldi S, et al.,  Journal of Acquired Immune Deficiency Syndromes. 1 June 2011 57(2) 157-64. 

No-Strings Deals Let Rivals Combine Unapproved Drugs
Morrison T, BioWorld Insight, 27 June 2011.

The pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques
Nuttall J, Kashuba A, Wang R, White N, et al., Antimicrobial Agents and Chemothererapy, October 2011.

Virtual drug discovery and development for neglected diseases through public-private partnerships
Nwaka S, Ridley RG. Nature Reviews Drug Discovery. November 2003, Vol 2:920-928.

Mucosal Immuniaztion: A Realistic Alternative
Otczyk D, Cripps A, Human Vaccine. December 2010 6(12) 978-1006.

International reproductive health still worth the investment
Petroni S, Shields W, Contraception. June 2011.

Effect of hormonal contraceptive methods on HIV disease progression: a systematic review
Phillips SJ, Curtis KM, Polis CB
AIDS 2013, 27: 787-794

Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence
Polis CB, Curtis KM
Lancet Infec Dis 2013, 13: 797-808.

Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence
Polis CB, Phillips SJ, Curtis MK
AIDS 2013, 27:493-505

Foreign Policy: Without Birth Control, Planet Doomed
Potts M, Campbell M, NPR. 11 May 2011.

Effect of Pap Smear Collection and Carageenan on Cervicovaginal Human Papillomavirus-16 Infection in a Rhesus Macaque Model
Roberts J, Kines R, Katki H, Lowy D, Scholler J, Journal of the National Cancer Institute. 6 April 2011  103(7) 1-7.

Genital Transmission of HPV in a Mouse Moel is Potentiated by Nonoxynol-9 and Inhibited by Carrageenan
Roberts J, Buck C, Thompson C, Kines R, Bernardo M, Choyke P, et al., Nature Medicine. July 2007 13(7) 857-61.

The Emerging Fourth Sector
Sabeti H with the Fourth Sector Network Concept Working Group. Executive Summary, The Aspen Institute, Washington, DC. 1998-2009.

Scientists and the media must give a balanced view: A reported link between hormonal contraception and HIV infection deserved a more critical look
Shelton J. Nature. November 2011. Vol 479:7.

Efficacy of Behavioral Interventions to Increase Condom Use and Reduce Sexually Transmitted Infections: A Meta-Analysis, 1991 to 2010
Scott-Sheldon, LAJ,  Huedo-Medina TB,  Warren MR, Johnson BT, Carey MP. Journal of Acquired Immune Deficiency Syndromes, 15 December 2011  58(5) 489-498.

Baseline correlates of inconsistent and incorrect condom use among sexually active women in the contraceptive CHOICE Project
Shih SL, Kebodeaux CA, Secura GM, Allsworth JE, Madden T, Peipert JF, Sexually Transmitted Diseases. Nov 2011 38(11):1012-19.

HIV/STIs and Pregnancy Prevention, Using a Cervical Barrier and Microbicide
Shihata A, Brody S
World Journal of AIDS, 2011, Vol. 1 131-135
Published Online December 2011 (

Assessment of Relevant Cultural Considerations is Essential for the Success of a Vaccine
Stanton B. Journal of Health, Population and Nutrition. September 2004, Vol 22,3:286-292.

FDA Study: Newer contraceptives carry higher risks
Staton T, FiercePharma. 28 October 2011.

Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection
Stapleton A, Au-Yeung M, Hooton T, Fredricks D, Roberts P, Czaja C, et al., Clinical Infectious Diseases. 2011  52 (10) 1212-17.

Microbicides: Ways Forward
Stone A, Harrison P, Report for Alliance for Microbicide Development 2010.

Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies
Thurman AR, Clark MR, Doncel GF. Infect Dis Obstet Gynecol. August 2011.

Emerging Antibody Prodictus and Nocotiana Manufacturing
Whaley K, Hiatt A, Zeitlin L, Human Vaccines. March 2011 7(3) 1-8.

Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines
Whaley K, Hanes J, Shattock R, Cone R, Friend D, Antiviral Research. December 2010.

Development of Novel Combination Therapies
Woodcock J, Griffin J, Behrman R, New England Journal of Medicine. 17 March 2011 364(11).

Efficient Mucosal Vaccination Mediated by the Neonatal Fc Receptor
Ye L, Zeng R, Bai Y, Roopenian D, Zhu X, Nature Biotechnology. February 2011 29(2) 158-163.

Ye FcRn Supplemental Information
Nature Biotechnology doi: 10.1038.nbt.1742

Behavioral Research on Biomedical Sexual Health Technologies: Opportunities and Directions
Zimet GD. Perspectives on Sexual and Reproductive Health, March 2010, Vol 42,1.

No Author:

Hormonal Contraceptives and HIV Risk – Emerging Evidence in Context
Guttmacher Institute, Fall 2011.

Rwanda: Trial of microbicide ring in final phase
IRIN PlusNews, 23 May 2011.

Technical Brief: Hormonal Contraception and HIV
PEPFAR/USAID. September 2013.

Condom technology leaps forward with radical design concepts for the 21st century
PR Web, 23 June 2011.

The Past, Present, and Future of HIV Microbicide Research Advocacy: An Interview with Polly Harrison, founder of the Alliance for Microbicide Development
Treatment Action Group. tagline. Winter 2011. 

Groundbreaking trial results confirm HIV treatment prevents transmission of HIV
UNAIDS/WHO, 12 May 2011. American Journal of Reproductive Immunology, March 2011  65(3).
Special Issue: Sexual Transmission of HIV in the 21st Century

USAID response to new findings on hormonal contraception and HIV acquisition in uninfected women and HIV transmission from infected women to male partners
USAID. October 2011.

Briefing Note: Hormonal Contraceptives and HIV
World Health Organization. October 2011.


BJOG Multipurpose Prevention Technologies: maximizing positive synergies

Click here to read CAMI Health press release announcing the BJOG release.